These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24248320)

  • 1. Severe digital necrosis in a 4-year-old boy: primary Raynaud's or jellyfish sting.
    Binnetoglu FK; Kizildag B; Topaloglu N; Kasapcopur O
    BMJ Case Rep; 2013 Nov; 2013():. PubMed ID: 24248320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iloprost treatment of finger gangrene in a patient with Raynaud's syndrome.
    Levy Y; Sherer Y; Shoenfeld Y
    Isr Med Assoc J; 2000 Dec; 2(12):960-1. PubMed ID: 11344792
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of alprostadil and iloprost in digital necrosis due to secondary Raynaud's phenomenon.
    Lamprecht P; Schnabel A; Gross WL
    Br J Rheumatol; 1998 Jun; 37(6):703-4. PubMed ID: 9667634
    [No Abstract]   [Full Text] [Related]  

  • 4. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
    Black CM; Halkier-Sørensen L; Belch JJ; Ullman S; Madhok R; Smit AJ; Banga JD; Watson HR
    Br J Rheumatol; 1998 Sep; 37(9):952-60. PubMed ID: 9783759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raynaud's phenomenon and gangrene following snake envenomation.
    Sathyanathan VP; Mathew MT
    J Assoc Physicians India; 1993 Feb; 41(2):122-3. PubMed ID: 8335605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of ischaemic digital ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis.
    Zachariae H; Halkier-Sørensen L; Bjerring P; Heickendorff L
    Acta Derm Venereol; 1996 May; 76(3):236-8. PubMed ID: 8800308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iloprost treatment for refractory Raynaud's phenomenon in two infants.
    Shouval DS; Mukamel M; Zulian F; Amir J; Harel L
    Clin Exp Rheumatol; 2008; 26(3 Suppl 49):S105-7. PubMed ID: 18799065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Digital gangrene in a patient with primary Raynaud's phenomenon.
    Ravindran V; Rajendran S
    J R Coll Physicians Edinb; 2012 Mar; 42(1):24-6. PubMed ID: 22441059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-traumatic Digital Gangrene Associated with Epinephrine Use in Primary Raynaud's Phenomenon: Lesson for the Future.
    Sama CB
    Ethiop J Health Sci; 2016 Jul; 26(4):401-4. PubMed ID: 27587939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Raynaud's phenomena: diagnostic and treatment study].
    Priollet P
    Rev Prat; 1998 Oct; 48(15):1659-64. PubMed ID: 9814067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis.
    Pope J; Fenlon D; Thompson A; Shea B; Furst D; Wells G; Silman A
    Cochrane Database Syst Rev; 2000; 1998(2):CD000953. PubMed ID: 10796395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Difficulties in diagnosis and treatment of severe secondary Raynaud's phenomenon in a Cameroonian woman: a case report.
    Agbor VN; Njim T; Aminde LN
    J Med Case Rep; 2016 Dec; 10(1):356. PubMed ID: 27998297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thromboangiitis obliterans: a rare cause of a reversible Raynaud's phenomenon.
    Noël B; Krayenbühl B; Cerottini JP; Guggisberg D; Buxtorf K; Pires A; Panizzon RG
    Dermatology; 2000; 200(4):363-5. PubMed ID: 10894979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral L-arginine can reverse digital necrosis in Raynaud's phenomenon.
    Rembold CM; Ayers CR
    Mol Cell Biochem; 2003 Feb; 244(1-2):139-41. PubMed ID: 12701823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases.
    Torley HI; Madhok R; Capell HA; Brouwer RM; Maddison PJ; Black CM; Englert H; Dormandy JA; Watson HR
    Ann Rheum Dis; 1991 Nov; 50(11):800-4. PubMed ID: 1722967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raynaud's of the gut? Systemic sclerosis-associated microvascular ischaemic colitis responsive to intravenous iloprost.
    Pratap K; Penglase R; Roper E; Stoita A
    Rheumatology (Oxford); 2024 Aug; 63(8):e219-e221. PubMed ID: 38290764
    [No Abstract]   [Full Text] [Related]  

  • 20. Digital gangrene and Raynaud's phenomenon as complications of lung adenocarcinoma.
    Kopterides P; Tsavaris N; Tzioufas A; Pikazis D; Lazaris A
    Lancet Oncol; 2004 Sep; 5(9):549. PubMed ID: 15337484
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.